<DOC>
	<DOCNO>NCT01532089</DOCNO>
	<brief_summary>This randomized phase II trial study well erlotinib hydrochloride ( Tarceva ) without bevacizumab ( Avastin ) work treat patient stage IV non-small cell lung cancer ( NSCLC ) epidermal growth factor receptor ( EGFR ) mutation . Erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , bevacizumab , may block tumor growth different way target certain cell . Bevacizumab may also stop growth NSCLC block growth new blood vessel necessary tumor growth . It yet know whether erlotinib hydrochloride effective give alone bevacizumab treat patient NSCLC .</brief_summary>
	<brief_title>Erlotinib Hydrochloride With Without Bevacizumab Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine progression-free survival erlotinib ( erlotinib hydrochloride ) bevacizumab versus erlotinib alone purpose decide combination arm worth pursue phase III trial . SECONDARY OBJECTIVES : I . To investigate overall survival erlotinib bevacizumab versus erlotinib alone . II . To investigate response rate erlotinib bevacizumab versus erlotinib alone . III . To investigate progression-free survival patient exon deletion 19 exon 21 L858R EGFR point mutation . IV . To investigate toxicity erlotinib bevacizumab versus erlotinib alone use Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 . TERTIARY OBJECTIVES : I . To correlate EGFR mutation detect plasma deoxyribonucleic acid ( DNA ) detect tumor DNA . II . To estimate prevalence EGFR T790M resistance mutation pretreatment tumor biopsy use sensitive mutation detection method . III . To investigate progression free survival EGFR mutant NSCLC patient without concurrent EGFR T790M detect pre-treatment tumor specimen use allele specific quantitative polymerase chain reaction ( PCR ) . IV . To prospectively evaluate predictive value plasma VEGF-A level progression free survival patient treat erlotinib alone combination bevacizumab . OUTLINE : Patients randomize 1 2 treatment arm . ARM A : Patients receive erlotinib hydrochloride orally ( PO ) daily ( QD ) day 1-21 . ARM B : Patients receive erlotinib hydrochloride Arm A bevacizumab intravenously ( IV ) 30-90 minute day 1 . In arm , course repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3-6 month 6 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Histologic documentation primary lung carcinoma , nonsquamous histology activate epidermal growth factor receptor ( define deletion 19 exon 21 L858R mutation ) ; Note : EGFR mutation test must perform Clinical Laboratory Improvement Amendments ( CLIA ) certify lab ; either institutional commercial laboratory ( e.g . Genzyme , Response Genetics , etc ) ; laboratory report commercial laboratory report specific mutation detect , method detect exon 19 exon 21 L858R point mutation must available Stage IV disease accord 7th Edition American Joint Committee Cancer stag system Measurable disease Life expectancy &gt; = 12 month Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 9.0 g/dL Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 2.5 x ULN patient without liver bone metastasis ; &lt; 5 x ULN patient liver bone metastasis CockcroftGault calculate creatinine clearance &gt; = 45 ml/min creatinine = &lt; 1.5 x ULN Urine dipstick proteinuria &lt; 2+ urine protein/creatinine ( UPC ) ratio = &lt; 1.0 Note : patient discover &gt; = 2 + proteinuria dipstick urinalysis baseline undergo 24hour urine collection must demonstrate = &lt; 1 g protein 24 hour Negative pregnancy test do = &lt; 7 day prior randomization , woman childbearing potential Provide inform write consent Willing return Academic Community Cancer Research United ( ACCRU ) enrol institution followup Willing provide tissue blood sample correlative research purpose Mixed , nonsmall cell small cell tumor mix adenosquamous carcinoma predominant squamous component Prior chemotherapy treatment metastatic nonsmall cell lung cancer Any following : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Immunocompromised patient ( relate use corticosteroid ) include patient know human immunodeficiency virus ( HIV ) positive , per medical doctor ( MD ) discretion Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation , medical condition would limit compliance study requirement Receiving investigational agent would consider treatment primary neoplasm Other active malignancy = &lt; 3 year prior randomization ; EXCEPTIONS : non melanotic skin cancer carcinomainsitu cervix ; Note : history prior malignancy , must receive specific treatment ( i.e . hormonal therapy ) cancer History myocardial infarction evidence arterial thrombotic disease ( angina ) , symptomatic congestive heart failure ( New York Heart Association &gt; = grade 2 ) , unstable angina pectoris , cardiac arrhythmia ; Note : allow patient evidence active disease least 6 month prior randomization History cerebral vascular accident ( CVA ) transient ischemic attack ( TIA ) = &lt; 6 month prior randomization History bleed diathesis coagulopathy Inadequately control hypertension ( systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 100 mmHg antihypertensive medication ) ; Note : history hypertensive crisis hypertensive encephalopathy allow Current recent ( = &lt; 10 day prior randomization ) use aspirin ( &gt; 325 mg/day ) , clopidogrel ( &gt; 75 mg/day ) , prasugrel ( &gt; 10 mg/day ) Serious nonhealing wound , ulcer , bone fracture , undergone major surgical procedure , open biopsy , significant traumatic injury = &lt; 28 day core biopsy = &lt; 7 day prior randomization History abdominal fistula , gastrointestinal perforation , intraabdominal abscess = &lt; 6 month prior randomization Known hypersensitivity Chinese hamster ovary cell product recombinant human antibody History hemoptysis &gt; = grade 2 ( define bright red blood least 2.5 mL ) = &lt; 3 month prior randomization Known central nervous system ( CNS ) disease , except treat brain metastasis ; Note : treatment brain metastasis may include whole brain radiotherapy ( WBRT ) , radiosurgery ( RS ) ; Gamma Knife , linear accelerator ( LINAC ) , equivalent combination deem appropriate treating physician ; patient CNS metastasis treat neurosurgical resection brain biopsy perform = &lt; 3 month prior randomization exclude ; Note : craniotomy intracranial biopsy site must adequately heal , free drainage cellulitis , underlie cranioplasty must appear intact time randomization ; study treatment initiate &gt; 28 day follow last surgical procedure ( include biopsy , surgical resection , wound revision , major surgery involve entry body cavity ) Significant vascular disease ( e.g . aortic aneurysm surgical repair recent peripheral arterial thrombosis ) = &lt; 6 month prior randomization Radiotherapy site reason = &lt; 14 day prior randomization Receiving medication substance strong moderate inhibitor CYP3A4 ; use follow strong moderate inhibitor prohibit = &lt; 7 day prior randomization : Strong inhibitor CYP3A4 : indinavir ( Crixivan ) , nelfinavir ( Viracept ) , atazanavir ( Reyataz ) , ritonavir ( Norvir ) , clarithromycin ( Biaxin , Biaxin XL ) , itraconazole ( Sporanox ) , ketoconazole ( Nizoral ) , nefazodone ( Serzone ) , saquinavir ( Fortovase , Invirase ) , telithromycin ( Ketek ) Moderate inhibitor CYP3A4 : aprepitant ( Emend ) , erythromycin ( Erythrocin , E.E.S , EryTab , Eryc , EryPed , PCE , fluconazole ( Diflucan ) , grapefruit juice , verapamil ( Calan , Calan SR , CoveraHS , Isoptin SR , Verelan , Verelan PM ) , diltiazem ( Cardizem , Cardizem CD , Cardizem LA , Cardizem SR , Cartia XT , Dilacor XR , Diltia XT , Taztia XT , Tiazac ) Receiving medication substance inducer CYP3A4 ; use follow inducer prohibit = &lt; 7 day prior randomization : efavirenz ( Sustiva ) , nevirapine ( Viramune ) , carbamazepine ( Carbatrol , Epitol , Equetro , Tegretol , TegretolXR ) , modafinil ( Provigil ) , phenobarbital ( Luminal ) , phenytoin ( Dilantin , Phenytek ) , pioglitazone ( Actos ) , rifabutin ( Mycobutin ) , rifampin ( Rifadin ) , St. John 's wort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>